• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用变异系数通过F-FDG PET/CT测定晚期非小细胞肺癌患者糖酵解表型的异质性

Heterogeneity of Glycolytic Phenotype Determined by F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung Cancer.

作者信息

Pellegrino Sara, Fonti Rosa, Hakkak Moghadam Torbati Armin, Bologna Roberto, Morra Rocco, Damiano Vincenzo, Matano Elide, De Placido Sabino, Del Vecchio Silvana

机构信息

Department of Advanced Biomedical Sciences, University of Naples "Federico II", 80131 Naples, Italy.

Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.

出版信息

Diagnostics (Basel). 2023 Jul 22;13(14):2448. doi: 10.3390/diagnostics13142448.

DOI:10.3390/diagnostics13142448
PMID:37510192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10378511/
Abstract

We investigated the role of Coefficient of Variation (CoV), a first-order texture parameter derived from F-FDG PET/CT, in the prognosis of Non-Small Cell Lung Cancer (NSCLC) patients. Eighty-four patients with advanced NSCLC who underwent F-FDG PET/CT before therapy were retrospectively studied. SUVmax, SUVmean, CoV, total Metabolic Tumor Volume (MTV) and whole-body Total Lesion Glycolysis (TLG) were determined by an automated contouring program (SUV threshold at 2.5). We analyzed 194 lesions: primary tumors ( = 84), regional ( = 48) and non-regional ( = 17) lymph nodes and metastases in liver ( = 9), bone ( = 23) and other sites ( = 13); average CoVs were 0.36 ± 0.13, 0.36 ± 0.14, 0.42 ± 0.18, 0.30 ± 0.14, 0.37 ± 0.17, 0.34 ± 0.13, respectively. No significant differences were found between the CoV values among the different lesion categories. Survival analysis included age, gender, histology, stage, MTV, TLG and imaging parameters derived from primary tumors. At univariate analysis, CoV ( = 0.0184), MTV ( = 0.0050), TLG ( = 0.0108) and stage ( = 0.0041) predicted Overall Survival (OS). At multivariate analysis, age, CoV, MTV and stage were retained in the model ( = 0.0001). Patients with CoV > 0.38 had significantly better OS than those with CoV ≤ 0.38 ( = 0.0143). Patients with MTV ≤ 89.5 mL had higher OS than those with MTV > 89.5 mL ( = 0.0063). Combining CoV and MTV, patients with CoV ≤ 0.38 and MTV > 89.5 mL had the worst prognosis. CoV, by reflecting the heterogeneity of glycolytic phenotype, can predict clinical outcomes in NSCLC patients.

摘要

我们研究了变异系数(CoV)这一从F-FDG PET/CT得出的一阶纹理参数在非小细胞肺癌(NSCLC)患者预后中的作用。对84例在治疗前接受F-FDG PET/CT检查的晚期NSCLC患者进行了回顾性研究。通过自动轮廓程序(SUV阈值设定为2.5)确定SUVmax、SUVmean、CoV、总代谢肿瘤体积(MTV)和全身总病变糖酵解(TLG)。我们分析了194个病灶:原发性肿瘤(n = 84)、区域淋巴结(n = 48)和非区域淋巴结(n = 17)以及肝脏转移灶(n = 9)、骨转移灶(n = 23)和其他部位转移灶(n = 13);平均CoV分别为0.36±0.13、0.36±0.14、0.42±0.18、0.30±0.14、0.37±0.17、0.34±0.13。不同病灶类别之间的CoV值未发现显著差异。生存分析纳入了年龄、性别、组织学类型、分期、MTV、TLG以及源自原发性肿瘤的影像参数。单因素分析时,CoV(P = 0.0184)、MTV(P = 0.0050)、TLG(P = 0.0108)和分期(P = 0.0041)可预测总生存期(OS)。多因素分析时,年龄、CoV、MTV和分期被纳入模型(P = 0.0001)。CoV>0.38的患者OS显著优于CoV≤0.38的患者(P = 0.0143)。MTV≤89.5 mL的患者OS高于MTV>89.5 mL的患者(P = 0.0063)。联合CoV和MTV,CoV≤0.38且MTV>89.5 mL的患者预后最差。CoV通过反映糖酵解表型的异质性,可预测NSCLC患者的临床结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/468937dd5347/diagnostics-13-02448-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/b670039287e1/diagnostics-13-02448-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/d2c51a760156/diagnostics-13-02448-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/468937dd5347/diagnostics-13-02448-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/b670039287e1/diagnostics-13-02448-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/d2c51a760156/diagnostics-13-02448-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a534/10378511/468937dd5347/diagnostics-13-02448-g003.jpg

相似文献

1
Heterogeneity of Glycolytic Phenotype Determined by F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung Cancer.利用变异系数通过F-FDG PET/CT测定晚期非小细胞肺癌患者糖酵解表型的异质性
Diagnostics (Basel). 2023 Jul 22;13(14):2448. doi: 10.3390/diagnostics13142448.
2
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.18F-FDG PET/CT 总代谢肿瘤体积预测非小细胞肺癌患者预后的价值。
Ann Nucl Med. 2019 Dec;33(12):937-944. doi: 10.1007/s12149-019-01407-z. Epub 2019 Oct 14.
3
Coefficient of Variation in Metastatic Lymph Nodes Determined by F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors.F-FDG PET/CT测定的晚期非小细胞肺癌患者转移淋巴结的变异系数:与原发肿瘤变异系数的联合应用
Cancers (Basel). 2024 Jan 9;16(2):279. doi: 10.3390/cancers16020279.
4
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.全身 FDG-PET 代谢肿瘤负荷对非小细胞肺癌的独立预后价值。
Int J Comput Assist Radiol Surg. 2013 Mar;8(2):181-91. doi: 10.1007/s11548-012-0749-7. Epub 2012 May 30.
5
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
6
18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.18F-FDG PET/CT 和未经治疗的非小细胞肺癌患者的循环肿瘤细胞。
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3250-3259. doi: 10.1007/s00259-021-05260-z. Epub 2021 Feb 25.
7
The value on SUV-derived parameters assessed on F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer.基于 F-FDG PET/CT 的 SUV 衍生参数在预测非小细胞肺癌纵隔淋巴结转移中的价值。
BMC Med Imaging. 2023 Apr 5;23(1):49. doi: 10.1186/s12880-023-01004-7.
8
Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.基于基线 18F-FDG PET/CT 的各种代谢参数在接受铂类化疗的非小细胞肺癌患者中的作用作为预后标志物。
Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886.
9
Heterogeneity of SSTR2 Expression Assessed by Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors.应用 Ga-DOTATOC PET/CT 测量变异系数评估神经内分泌肿瘤患者中 SSTR2 的异质性。
J Nucl Med. 2022 Oct;63(10):1509-1514. doi: 10.2967/jnumed.121.262928. Epub 2022 Mar 10.
10
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.代谢肿瘤负荷 18F-FDG PET 在非手术治疗的非小细胞肺癌患者中的预后价值。
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):27-38. doi: 10.1007/s00259-011-1934-6. Epub 2011 Sep 23.

引用本文的文献

1
Texture Analysis of 68Ga-DOTATOC PET/CT Images for the Prediction of Outcome in Patients with Neuroendocrine Tumors.用于预测神经内分泌肿瘤患者预后的68Ga-DOTATOC PET/CT图像纹理分析
Biomedicines. 2025 May 23;13(6):1286. doi: 10.3390/biomedicines13061286.
2
Prognostic Value of Tumor Dissemination (Dmax) Derived from Basal 18F-FDG Positron Emission Tomography/Computed Tomography in Patients with Advanced Non-Small-Cell Lung Cancer.基于基础18F-FDG正电子发射断层扫描/计算机断层扫描得出的肿瘤播散(Dmax)在晚期非小细胞肺癌患者中的预后价值
Biomedicines. 2025 Feb 15;13(2):477. doi: 10.3390/biomedicines13020477.
3
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.

本文引用的文献

1
Role of Texture Analysis in Oropharyngeal Carcinoma: A Systematic Review of the Literature.纹理分析在口咽癌中的作用:文献系统评价
Cancers (Basel). 2022 May 16;14(10):2445. doi: 10.3390/cancers14102445.
2
Heterogeneity of SSTR2 Expression Assessed by Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors.应用 Ga-DOTATOC PET/CT 测量变异系数评估神经内分泌肿瘤患者中 SSTR2 的异质性。
J Nucl Med. 2022 Oct;63(10):1509-1514. doi: 10.2967/jnumed.121.262928. Epub 2022 Mar 10.
3
The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer.
18F-FDG PET/CT 图像变异系数和纹理分析预测多发性骨髓瘤患者的预后。
Ann Hematol. 2024 Sep;103(9):3713-3721. doi: 10.1007/s00277-024-05905-7. Epub 2024 Jul 24.
4
Machine Learning and Texture Analysis of [F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients.用于预测非小细胞肺癌患者远处转移的[F]FDG PET/CT图像的机器学习与纹理分析
Biomedicines. 2024 Feb 20;12(3):472. doi: 10.3390/biomedicines12030472.
5
Coefficient of Variation in Metastatic Lymph Nodes Determined by F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors.F-FDG PET/CT测定的晚期非小细胞肺癌患者转移淋巴结的变异系数:与原发肿瘤变异系数的联合应用
Cancers (Basel). 2024 Jan 9;16(2):279. doi: 10.3390/cancers16020279.
18F-FDG PET/CT 代谢、形态及异质性参数对非小细胞肺癌纵隔淋巴结转移的诊断价值。
Nucl Med Commun. 2021 Nov 1;42(11):1247-1253. doi: 10.1097/MNM.0000000000001456.
4
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images.利用 PET/CT 图像深度学习进行 PD-L1 状态的无创测量和免疫治疗反应预测。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2020-002118.
5
A Systematic Review of PET Textural Analysis and Radiomics in Cancer.正电子发射断层扫描(PET)纹理分析与放射组学在癌症中的系统评价
Diagnostics (Basel). 2021 Feb 23;11(2):380. doi: 10.3390/diagnostics11020380.
6
PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients.基于正电子发射断层扫描的体积生物标志物用于非小细胞肺癌患者的风险分层
Diagnostics (Basel). 2021 Jan 30;11(2):210. doi: 10.3390/diagnostics11020210.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
The Biological Meaning of Radiomic Features.放射组特征的生物学意义。
Radiology. 2021 Mar;298(3):505-516. doi: 10.1148/radiol.2021202553. Epub 2021 Jan 5.
9
Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives.放射组学在预测非小细胞肺癌治疗反应中的应用:现状、挑战与未来展望。
Eur Radiol. 2021 Feb;31(2):1049-1058. doi: 10.1007/s00330-020-07141-9. Epub 2020 Aug 18.
10
Introduction to Radiomics.放射组学简介。
J Nucl Med. 2020 Apr;61(4):488-495. doi: 10.2967/jnumed.118.222893. Epub 2020 Feb 14.